Have to go back a bit, but I seem to remember the relative attractive power of Prana's drugs was shown in a lovely chart. It's why they are considered attenuators, rather than chelators that have a higher "magnitude" of ion-grabbing power (providing I didn't misunderstand, mischaracterize or mistate the article and freely admit - this is a gross over-simplification). Sooo...I thought that PBT2 had a greater magnitude than PBT434 (in their power to attract certain ions), but I wonder how PBT434/Zn would work in reinvigorating antibiotics. Also if 434's affinity is less, then perhaps it should be used first and PBT2 kept in reserve? Or do I have it upside down and backwards. Come on Skint and PIvalde and fellow loyal sh/rooms - what do you think? Could a separate study with PBT434 do the same or better without the add-ons? These weren't human trials that were done. It's more likely glorified petri dishes, etc.
As long as Prana has the patents and rights...How are labs compensated? Lump sum, percentage, a pretty medal, a future affiliation that's symbiotic, or what? Shall we diddle with this for a few more of PBT2's remaining years?
It would be nice to see the share price respond to the news. Also, Didn't we just see a "... raise more capital by selling off some shares." It seems you'd want to have a higher price thus raise more capital...unless there's a sweetheart deal hiding in the bushes?
And, the clock ticks
Oh...listen...
PBT Price at posting:
4.1¢ Sentiment: Hold Disclosure: Held
